
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is a clinical-stage pharmaceutical company with 5 novel drug candidates, focused on treating Alzheimer's disease (AD). The company has recently changed its FYE and is on track for two major milestones in mid-2026, with over 70% patient enrollment in its Phase 2 CALMA trial and the completion of its AI beta program. Risks include failure to gain regulatory approvals and achieve suitable reimbursement.
Bears say
IGC Pharma is focused on developing cannabinoid-based formulations for treating diseases and conditions, specifically Alzheimer's disease. While the company has reported positive interim results for its investigational drugs, the long road ahead and the limited and transient effects of current Alzheimer's drugs indicate significant risks. Additionally, despite the large potential market for Alzheimer's treatments, the company only has two drugs in later stages of development, making it a high-risk investment.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares